JAZZ News and Press, Jazz Pharmaceuticals plc From 05/09/22

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2022 Q1 earnings call. For further details see: Jazz Pharmaceuticals plc 2022 Q1 - Results - Earnings Call Presentation

Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics PR Newswire DUBLIN , May 9, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has completed the divestiture of Sunosi ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Japan's Sumitomo Pharma entered into a licensing agreement under which Jazz acquired the rights to make and sell Sumitomo's investigational compound DSP-0187, which has the potential to treat narcolepsy, idiopathic hypersomnia and other sleep disorders. ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced financial results for the first quarter of 2022, raised 2022 financial guidance, and provided business updates. “We’re pleased to raise our top- and bottom-line guidance, driven by our continued execution and ...

THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and eve appetite, weight/BMI. In fact, in a study of 900 adults aged 21 and older in the U.S., InMed Pharmaceuticals Inc.’s (NASDAQ: INM) subsidiary, BayMedica, will be providing rare can...

Top Marijuana Stocks To Watch That May Be Overlooked By Investors Are marijuana stocks investors going to go back to fundamental trading. Right now there is a lot in the works for the cannabis industry as a whole. Many cannabis companies have released solid earnings over the last mo...

Jazz Pharmaceuticals plc (JAZZ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Andrea Flynn – Head-Investor Relations Bruce Cozadd – Chairman and Chief Executive Officer Dan Swisher – President Rob Iannone – Executive Vice President, G...

Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $3.73 misses by $0.16. Revenue of $813.72M (+33.9% Y/Y) misses by $40.01M. The Company is raising its full year 2022 financial guidance as follows: Revenues of $3,500M - $3,700M (prior $3,460M - $3,660M) vs. consensus o...

Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance PR Newswire DUBLIN , May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022...

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist PR Newswire Jazz licenses development and commercialization rights in U.S., Europe and oth...